

## SUPPLEMENTARY MATERIAL

**Table 1.** Selection criteria for Alergodata Registry patients

<b>Inclusion criteria</b>
<ul style="list-style-type: none"><li>• Adult patients or children over six years with a diagnosis of severe asthma, whether or not treated with biological drugs according to the SPC approved in Spain*.</li><li>• Patients diagnosed with chronic rhinosinusitis with nasal polyps and/or chronic urticaria and/or moderate to severe atopic dermatitis that receive treatment with biological drugs according to the SPC approved in Spain*†.</li><li>• Patients that are seen in allergology clinics.</li><li>• Patients who have signed informed consent to participate in the study.</li></ul>
<b>Exclusion criteria</b>
<ul style="list-style-type: none"><li>• Patients with a medical or psychological disorder that could limit their ability to understand and/or answer questions and complete questionnaires or patients who, in the opinion of the investigator, are unlikely to collaborate sufficiently.</li></ul>

\* All biological drugs approved in the SPC approved in Spain at the time of the inclusion of the patient to the study may be included in the registry.

† The age of inclusion will be determined according to the SPC approved in Spain\* for the different biological drugs in each disease.

**Table 2.** Most relevant clinical and socio-demographic variables of the patients included in the Alergodata Registry

<b>Clinical and socio-demographic variables</b>	<b>Severe Asthma</b>	<b>Severe Asthma<sup>a</sup> with CRSwNP</b>
<b>Age</b>	<b>N=170</b>	<b>N=30</b>
Adults, Mean ± SD (n)	50.6 ± 14.4 (n=158)	51.4 ± 12.4
Children, Mean ± SD (n)	13.8 ± 3.8 (n=12)	N/A
<b>Sex</b>	<b>N=170</b>	<b>N=30</b>
<b>Woman (%)</b>	64.1%	50.0%
<b>Body Mass Index (kg/m<sup>2</sup>), Median (Q1; Q3)</b>	27.0 (23.8; 32.1)	25.3 (23.6,29.2)
<b>Smoking habits</b>	<b>N=158</b>	<b>N=29</b>
Non-smoking, n (%)	150.0 (94.90%)	28.0 (96.6%)
Former smokers, n (%)	41.0 (27.30%)	8.0 (28.6%)
<b>Comorbidities (%)</b>	<b>N=170</b>	<b>N=30</b>
CRSwNP <sup>a</sup>	44.1%	N/A
CRS without nasal polyps	7.1%	N/A
Atopic Dermatitis <sup>a</sup>	10.0%	10.0%
Rhinitis	68.0%	65.5%
Gastroesophageal reflux	17.1%	10.0%
Psychiatric disturbance	11.8%	6.67%
Respiratory disease exacerbated by NSAIDs	18.2%	50.0%
Bronchiectasis	7.7%	10.0%
Obstructive sleep apnea	7.1%	6.9%
<b>Exacerbations, Mean ± SD</b>	1.9 ± 2.3 (N=143)	N/A
<b>Level of asthma control, n (%)</b>	<b>N=132</b>	
Controlled	27.0 (20.5%)	N/A
Uncontrolled	105.0 (79.5%)	N/A
Need for admission to ICU	5.0 (3.4%)	N/A
<b>Phenotypes of asthma (%)</b>	<b>N=146</b>	<b>N=22</b>
Eosinophilic (T2)	47.9%	77.3%
Allergic (T2)	50.7%	22.7%
Non-eosinophilic	1.4%	0.0%
<b>Symptoms trigger, n (%)</b>	<b>N=137</b>	<b>N=18</b>
Infections, n (%)	34.0 (24.8%)	4 (22.2%)
Irritants, n (%)	24.0 (17.5%)	3 (16.7%)
Allergens, n (%)	62.0 (44.5%)	6 (33.3%)
Exercise, n (%)	9.0 (6.57%)	1 (5.56%)
Others**, n (%)	8.0 (6.57%)	4 (22.2%)
<b>Inflammatory characteristics</b>		
Eosinophils in peripheral blood (cell/mm <sup>3</sup> ), Mean ± SD.	519.0 ± 577.0 (N=122)	
Eosinophils in sputum (%)	20.0% (N=1)	
IgE Total serum (kU/L), Mean ± SD.	551.0 ± 775.0 (N=125)	
FE <sub>NO</sub> (ppb), Mean ± SD.	55.2 ± 53.9 (N=83)	

<b>Conventional treatments, %</b>		<b>N=170</b>	<b>N=23</b>
ICS/LABA combination	93.5%		96.3%
SABA	62.4%		27%
Montelukast	77.7%		59.3%
LAMA (one or more devices)	55.9%		44.4%
Intranasal corticosteroids	58.2%		92.6% %
Antihistamines	55.3%		55.6%
Allergen-specific immunotherapy (ASIT)	10.1% (N=169)		8.0%
Systemic corticosteroids	24.7%		7.4% (N=16)
<b>Cumulative annual dose (prednisone), Mean ± SD</b>	839.0 ± 3801.0 (N=131)		
<b>Clinically relevant allergic sensitization, (%)</b>	65.9% (N=170)		60.0% (N=30)
<b>Prescribed biologic treatment, % (N)</b>			
Omalizumab	28.6% (N=168)		12.5% (N=24)
Dupilumab	27.9% (N=165)		69.6% (N=23)
Mepolizumab	23.4% (N=167)		20.8% (N=24)
Benralizumab	20.4% (N=157)		4.2% (N=24)
Reslizumab	3.8% (N=158)		4.0% (N=25)
<b>Questionnaires</b>			
ACT (asthma), Mean ± SD	15.5 ± 5.2 (N=132)		N/A
ACT (asthma and CRSwNP), Mean ± SD	N/A		15.4 ± 5.4 (N=20)
SNOT (asthma and CRSwNP), Mean ± SD	N/A		50.9 ± 25.3 (N=23)
TPS (asthma and CRSwNP), Mean ± SD	N/A		3.9 ± 2.7 (N=13)

<sup>a</sup> (with or without associated biologic treatment)

\*Others: NSAIDs, metamizol, eosinophilic esophagitis, lipid transfer protein, pyrazonic medicines, penicillin, prophyryns, thiomersal, feathers.

N/A, Not applicable; CRSwNP, chronic rhinosinusitis with nasal polyps; CRS, chronic rhinosinusitis; COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; LABA, Long-acting beta-agonists; SABA, Short-acting beta-agonists; LAMA, long acting muscarinic antagonist;